--- title: "Annovis Bio 10-K: Net loss $28.9M; Cash $19.5M, runway into Q3 2026" type: "News" locale: "en" url: "https://longbridge.com/en/news/279095357.md" description: "Annovis Bio reported a net loss of $28.9 million for the year, an increase from $24.6 million in 2024, primarily due to higher clinical spending. The company has $19.5 million in cash, which is insufficient to fund operations beyond 12 months, providing a runway into Q3 2026. Key highlights include a pivotal Phase 3 Alzheimer’s trial and a Parkinson’s disease extension study. R&D expenses rose to $25.2 million, while general and administrative costs decreased. Additional fundraising is critical for ongoing trials and operations." datetime: "2026-03-13T21:25:01.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/279095357.md) - [en](https://longbridge.com/en/news/279095357.md) - [zh-HK](https://longbridge.com/zh-HK/news/279095357.md) --- # Annovis Bio 10-K: Net loss $28.9M; Cash $19.5M, runway into Q3 2026 **Annovis Bio** reported a net loss of $28.9 million for the year, wider than the $24.6 million loss in 2024, driven by higher clinical spending and operating expenses. The company held $19.5 million in cash and cash equivalents at year-end, which management indicates is insufficient to fund operations for more than 12 months and gives a runway into the third quarter of 2026. Operating losses reflect elevated R&D investment related to a pivotal Phase 3 Alzheimer’s disease trial and ongoing clinical programs. **Financial Highlights** - **Net loss:** $28.9 million (increase of $4.3 million vs. $24.6 million in 2024) - **Total operating expense:** $29.7 million (up $3.0 million vs. $26.7 million in 2024) - **Research and development:** $25.2 million (up $5.2 million vs. $20.0 million in 2024) - **General and administrative:** $4.5 million (down $2.2 million vs. $6.7 million in 2024) - **Cash and cash equivalents:** $19.5 million; cash runway into Q3 2026 and insufficient to fund operations for more than 12 months **Business Highlights** - **Clinical programs:** Initiated an FDA-cleared pivotal Phase 3 Alzheimer’s disease trial enrolling 760 patients in February 2025. - **Extension study:** Began a 36-month open-label Parkinson’s disease extension in January 2026 to continue assessing longer-term effects. - **Efficacy signals & biomarkers:** Prior Alzheimer’s and Parkinson’s trials showed dose-dependent cognitive and motor improvements with supporting CSF and plasma biomarker validation (including p‑tau217 and MRI measures). - **R&D operations:** Year-over-year R&D spending rose due to Phase 3 trial execution; the company expects elevated clinical activity into 2026 and continues to rely on third-party CROs and CMOs. - **Capital strategy:** Completed multiple equity offerings and ATM sales in 2024–2025 to provide funding, but additional fundraising is critical to sustain ongoing trials and operations. Original SEC Filing: Annovis Bio, Inc. \[ ANVS \] - 10-K - Mar. 13, 2026 **Disclaimer** This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC. ### Related Stocks - [000933.CN](https://longbridge.com/en/quote/000933.CN.md) - [588860.CN](https://longbridge.com/en/quote/588860.CN.md) - [516820.CN](https://longbridge.com/en/quote/516820.CN.md) - [159938.CN](https://longbridge.com/en/quote/159938.CN.md) - [562600.CN](https://longbridge.com/en/quote/562600.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [159883.CN](https://longbridge.com/en/quote/159883.CN.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) - [159102.CN](https://longbridge.com/en/quote/159102.CN.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [560600.CN](https://longbridge.com/en/quote/560600.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [510660.CN](https://longbridge.com/en/quote/510660.CN.md) - [516610.CN](https://longbridge.com/en/quote/516610.CN.md) - [513060.CN](https://longbridge.com/en/quote/513060.CN.md) - [159929.CN](https://longbridge.com/en/quote/159929.CN.md) - [513290.CN](https://longbridge.com/en/quote/513290.CN.md) ## Related News & Research - [Xuanzhu Biopharm Wins Green Light for Phase III Anaprazole Trial in H. pylori](https://longbridge.com/en/news/282752451.md) - [Anthropic adds Novartis CEO Vas Narasimhan to its board](https://longbridge.com/en/news/282719936.md) - [Theralase(R) Closes $CAN 2.66 Million Financing | TLTFF Stock News](https://longbridge.com/en/news/282333628.md) - [Pluxee (ENXTPA:PLX) Valuation Check After Recent Share Price Rebound](https://longbridge.com/en/news/282749537.md) - [TransThera Sciences Launches Discounted HK$290 Million H-Share Placement](https://longbridge.com/en/news/282767094.md)